Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Surpassing 1,000 Company Owned Company Operated stores
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru
Subscribe To Our Newsletter & Stay Updated